Pharmaceutical Tablet Manufacturing – Isoniazid 300 mg

The contract calls for the manufacture and supply of Isoniazid Tablets USP, 300 mg, packaged in bottles containing 100 tablets each, with full compliance to U.S. Pharmacopeia standards, FDA current Good Manufacturing Practices, and Defense Logistics Agency packaging and labeling requirements. The product must meet strict quality and regulatory benchmarks to ensure safety, efficacy, and uniformity, targeting use within the Department of Defense’s medical supply chain. The solicitation is structured as a subcontract under NAICS code 325412, indicating classification within pharmaceutical and biomedical manufacturing, and the place of performance is designated as FPO with ZIP code 96692, suggesting delivery to military or federal facilities via overseas or expeditionary channels. Responses are due by August 3, 2026, with the opportunity posted on July 27, 2026, allowing approximately one week for submission. The contracting entity is the Medical Supply Chain Pharm FSA under the Department of Defense, which manages critical pharmaceutical logistics for U.S. armed forces. The contract requires full adherence to DLA’s stringent documentation, traceability, and packaging protocols, ensuring that each unit is properly labeled, sterile, and ready for immediate use in deployed or institutional medical settings. Submission must be made via the DIBBS platform at the provided URL, and bidders must demonstrate capacity to consistently deliver pharmaceutical-grade Isoniazid under cGMP conditions without interruption.